Hadrien Chef

Hadrien works closely with many different types of clients in Belgium’s thriving tech, pharma, and biotech landscape. From start-ups to multinationals, his advice helps clients identify how to succeed and grow as a business.

Hadrien is an experienced corporate lawyer who specialises in mergers and acquisitions (M&A), venture capital, public offerings, corporate reorganisations, corporate and securities law, and corporate finance. As a Partner in Osborne Clarke’s Brussels corporate team, he advises on public and private M&A and acts for clients on a wide variety of transactional matters and restructurings, including setting up, financing, reorganising, acquiring, or liquidating business ventures; he also provides litigation services in these areas. He furthermore supports clients with ECM, prospectus issuance, and advice on market abuse and related disputes. He also supports insurance companies and intermediaries with their regulatory needs and defends them before Belgian and international regulators.

Hadrien works with clients at the cutting edge of pharma, biotechnology, and medtech. His clients active in this sector include Sunrise, Kiomed, BioKuris, BioSenic, ImmunXperts, Delphi Genetics, Vesale Pharma, Kitozyme, Gabi Smartcare, Tasso, OncoDNA, Stellaris, and BepharBel Manufacturing. He also works with funds like Circular Innovation Fund, Takeda Ventures, Gilde Healthcare, AdBio, Vives, Elaia, and Andera Partners.

While an undisputed specialist in life sciences, Hadrien has significant expertise in other areas, including technology, ESG, transportation, and automotive, regularly advising on M&A transactions, joint ventures, and investment schemes. In particular, he works with technology companies active in Belgium and throughout Europe, helping them with strategic partnerships, investments, and acquisitions. For example, he has recently advised Safran, P&V Assurances, Carmeuse Ventures, Audiense, Acapela, Bolt, Cream Consulting, and Fortino Capital on acquisitions, sales, or investments; and Aidoptation, Merchery, Greentripper, and Greenomy on financing rounds or exits.